Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Stopped The data met the protocol-specified criteria for futility of the investigational treatment.

Conditions

• Leukemia, Myeloid, Acute

Interventions

• DRUG: DFP-10917
• DRUG: Cytarabine
• DRUG: Azacitidine
• DRUG: Decitabine
• DRUG: Mitoxantrone
• DRUG: Etoposide
• DRUG: Fludarabine
• DRUG: Idarubicin
• DRUG: Venetoclax
• DRUG: Cladribine

Sponsor

Delta-Fly Pharma, Inc.